Pulse Biosciences (PLSE) Corporate presentation summary

Mission and vision

• Aims to design, produce, and commercialize nano-pulse technology to improve patient outcomes.

• Focuses on high-quality, reliable products developed with rigorous scientific and clinical standards.

• Seeks to positively impact patients, healthcare providers, shareholders, and team members.

Leadership and expertise

• Leadership team includes experienced executives from major medtech firms and renowned clinicians.

• Board of directors features industry veterans and scientific experts.

Financial and strategic position

• Ended 2025 with $80.7M in cash and no debt.

• Used $54.1M in operating activities in 2025, with increased cash burn to support clinical opportunities.

• 4Q25 revenue was $264K; insider ownership is approximately 75%.

• Strategic focus on EP cardio ablation product following strong EU clinical data.